Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
47 hedge funds and large institutions have $808M invested in Centessa Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 7 reducing their positions, and 8 closing their positions.
171% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 7
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
18% more funds holding
Funds holding: 40 → 47 (+7)
16.64% more ownership
Funds ownership: 63.31% → 79.95% (+17%)
15% less capital invested
Capital invested by funds: $947M → $808M (-$140M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.7M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$10.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.79M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$6.12M |
| 5 |
BlackRock
New York
|
+$3.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$8.27M |
| 2 |
Millennium Management
New York
|
-$5.63M |
| 3 |
Jennison Associates
New York
|
-$4.95M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$4.66M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.61M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
51
Brookfield Corp
Toronto,
Ontario, Canada
| – | -$447K | -26,788 | Closed |
|
|
GCM
52
Ghisallo Capital Management
Boston,
Massachusetts
| – | -$251K | -15,000 | Closed |
|
53
D.E. Shaw & Co
New York
| – | -$207K | -12,420 | Closed |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$8K | -453 | Closed |
|
|
EWA
55
Evolution Wealth Advisors
Aventura,
Florida
| – | -$3K | -160 | Closed |
|
CNTA Hedge Fund Activity: Q4 2021 in Review
47 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q4 2021, worth a combined $808M — down 15% from $947M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CNTA positions and 8 closed out — a net gain of 7 holders — while 19 added to existing stakes and 7 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $10.7M. The largest seller was Logos Global Management, cutting an estimated $8.27M.
- 47 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q4 2021, up from 40 in Q3 2021.
- Funds reported $808M of Centessa Pharmaceuticals stock for Q4 2021, down 15% quarter-over-quarter.
- 15 funds opened new Centessa Pharmaceuticals positions in Q4 2021 and 8 closed out, a net change of +7 holders.
- The largest Centessa Pharmaceuticals buyer in Q4 2021 was Point72 Asset Management, an estimated $10.7M added.
- The largest Centessa Pharmaceuticals seller in Q4 2021 was Logos Global Management, an estimated $8.27M sold.
Based on aggregated 13F filings for Q4 2021.